ArcticZymes Technologies announces closing of Biotec BetaGlucans divestment

Tromsø, Norway, 31. December 2020. With reference to announcement made on 14. December 2020, ArcticZymes Technologies ASA (AZT) announces closing of the Biotec BetaGlucans AS divestment.

Under the terms of the share purchase agreement (SPA) signed between ArcticZymes Technologies ASA and Lallemand Inc’s subsidiary, Danstar Ferment AG, all closing conditions are fulfilled. In line with the SPA, ArcticZymes Technologies has today received a consideration of NOK 70 million on a cash free, debt-free basis. Closing of customary accounts adjustments will be completed when annual figures are finalised.

For more information, please contact:

ArcticZymes Technologies
Børge Sørvoll, CFO
Tel: +47 95 29 01 87